Paper Details

  1. Home
  2. Paper Details

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.

Author: AccordinoMelissa K, AhnHeejoon, AndreopoulouEleni, BaerLea N, ChiuzanCodruta, CrewKatherine D, GradisharWilliam J, HershmanDawn L, KalinskyKevin, MundiPrabhjot S, NovikYelena, O'DeaAnne, O'ReganRuth, OhSun Y, RaptisGeorge, ReidSonya A, SakachElizabeth, SatheClaire, Stringer-ReasorErica, TierstenAmy, TrivediMeghna S, WisinskiKari B, ZelnakAmelia B

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

CDK4/6 inhibitors are medications that are used to treat breast cancer. This abstract describes a study that is investigating whether it is beneficial to continue using a CDK4/6 inhibitor after the cancer has progressed.
Paper Details　
Original Abstract of the Article :
Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Although preclinical and clinic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.22.02392

データ提供：米国国立医学図書館（NLM）

Endocrine Therapy and CDK4/6 Inhibitors: A Promising Combination

Dr. Camel here, ready to embark on a journey through the evolving landscape of breast cancer treatment! This research explores a novel combination therapy using endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). It's like finding a new oasis in the desert of breast cancer research, offering hope for improved treatment outcomes.

A New Era of Breast Cancer Treatment

The study investigates the efficacy of continuing CDK4/6i treatment at disease progression, switching to a different endocrine therapy. It's a new approach, like finding a different path through a challenging desert. This research highlights the potential of this combination therapy to extend progression-free survival (PFS) and overall survival (OS) in patients with HR+ HER2- MBC.

A Promising Future

The findings of this study suggest a promising future for this combination therapy. It's a ray of hope in the desert of breast cancer research, offering a potential path towards better treatment outcomes. The study underscores the importance of further research to confirm these findings and explore the optimal sequencing and duration of CDK4/6i and endocrine therapy.

Dr. Camel's Conclusion

This research showcases the relentless quest for improved treatments for breast cancer. It highlights the potential of combining CDK4/6i and endocrine therapy to enhance outcomes for patients with HR+ HER2- MBC. It's a journey through the desert of cancer research, where we continue to search for innovative solutions and better treatments to improve the lives of patients.

Date :
  1. Date Completed 2023-08-18
  2. Date Revised 2023-08-21
Further Info :

Pubmed ID

37207300

DOI: Digital Object Identifier

10.1200/JCO.22.02392

Related Literature

Article Analysis
・Effects of ribociclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.